Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
24.07.23 | GreenLight Biosciences: GreenLight Announces Completion of Merger with Fall Line Endurance Fund | 549 | GlobeNewswire (Europe) | LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) ("GreenLight" or the "Company") today announced the closing of its previously announced merger... ► Artikel lesen | |
20.07.23 | GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares | 361 | GlobeNewswire (Europe) | LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) ("GreenLight" or the "Company") today announced that it is initiating the final steps in closing... ► Artikel lesen | |
30.05.23 | GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private Transaction | 301 | GlobeNewswire (Europe) | LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) ("GreenLight" or the "Company") today announced that the Company has entered into a definitive... ► Artikel lesen | |
11.05.23 | GreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress | 243 | GlobeNewswire (Europe) | BOSTON, May 11, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences, PBC (Nasdaq: GRNA), a biotechnology company dedicated to making RNA products affordable and accessible for human health and agriculture... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
REPLENISH NUTRIENTS | 0,049 | +5,19 % | EARTHRENEW: ESGFIRE comments on Replenish Nutrients 2023 financials | ||
FATE THERAPEUTICS | 3,716 | +0,51 % | Fate Therapeutics, Inc.: Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting | Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refractory... ► Artikel lesen | |
QIAGEN | 39,585 | +1,29 % | Qiagen bekräftigt Prognose für 2024 - erste Expertenstimmen | Das Biotech-Unternehmen Qiagen meldet für das erste Quartal 2024 einen Umsatzrückgang von 485,4 Millionen Dollar auf 458,8 Millionen Dollar. Das Betriebsergebnis ist leicht gefallen und liegt bei 94... ► Artikel lesen | |
EVOTEC | 9,895 | +1,59 % | Allianz, Andritz, CureVac, Deutsche Telekom, Evotec - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
MORPHOSYS | 66,10 | -0,15 % | MorphoSys: Effekte der Novartis-Übernahmeofferte sorgen für hohen Quartalsverlust | Übernahmekandidat MorphoSys schließt das erste Quartal 2024 mit einem Verlust im fortgeführten Geschäft von 311 Millionen Euro ab nach 32,2 Millionen Euro Minus im Vorjahresquartal. Der Umsatz steigt... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 44,000 | -6,06 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
BIONTECH | 85,65 | +2,39 % | Moderna Aktie zieht BioNTech davon - Zahlen besser als erwartet | BioNTechs großer US-Konkurrent Moderna hat am Donnerstag Quartalszahlen vorgelegt - und der Aktienkurs des Biotech-Unternehmens reagiert äußerst positiv. Aktuell gewinnt der Titel an der US-Techbörse... ► Artikel lesen | |
CYTOMX THERAPEUTICS | 4,166 | +171,93 % | CytomX-Aktie +259%: Top-Empfehlung dreht völlig durch! | Mit der Aktie des Biotech-Unternehmens CytomX Therapeutics (WKN: A14158) knallt einer unserer Top-Tipps am Mittwoch in der Spitze um +259% von 1,63 US$ bis auf 5,85 US$ in die Höhe - bei absoluten Rekordumsätzen... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 8,445 | +1,26 % | Recursion Pharmaceuticals: Recursion to Participate in Upcoming Investor Conferences | ||
MODERNA | 116,00 | +12,25 % | Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars | ||
JANUX THERAPEUTICS | 58,80 | +1,05 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
CABALETTA BIO | 12,500 | +0,73 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
MERRIMACK PHARMACEUTICALS | 15,000 | +0,17 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
BEAM THERAPEUTICS | 22,390 | +2,99 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
DYNE THERAPEUTICS | 25,620 | -0,81 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen |